Evaluation of NeoRetina Artificial Intelligence Algorithm for the Screening of Diabetic Retinopathy at the CHUM

Diabetic Retinopathy Clinical Trial

— DR-NeoRetina  

Official title:

The Use of Artificial Intelligence in the Early Detection and the Follow-Up of Diabetic Retinopathy of Diabetic Patients Followed at the CHUM: Evaluation of NeoRetina Automated Algorithm (DIAGNOS Inc.)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04699864
• Other study ID #: 20.292
• Status: Not yet recruiting
• Phase: N/A
• Start date: April 2024
• Est. completion date: December 2026

Study information

• Verified date: February 2024
• Source: Centre hospitalier de l'Université de Montréal (CHUM)
• Contact: Marie-Catherine Tessier, MSc
• Phone: 514-890-8000
• Email: marie-catherine.tessier.chum[@]ssss.gouv.qc.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This prospective study aims to validate if NeoRetina, an artificial intelligence algorithm developped by DIAGNOS Inc. and trained to automatically detect the presence of diabetic retinopathy (DR) by the analysis of macula centered eye fundus photographies, can detect this disease and grade its severity.

Description:

More than 880 000 Quebecers (more than 10% of the population) suffer from diabetes, which is the main cause of blindness in diabetic adults under 65 years of age, and around 40% of people with diabetes suffer from diabetic retinopathy (DR). The early detection of DR and a regular follow-up is thus crucial to prevent the progression of this disease.

However, the public health care system in Quebec does not actually have the capacity to allow all people with diabetes to see an ophthalmologist within a short delay. Artificial intelligence might help in screening DR and in refering to eye doctors only patients who suffer from this eye disease.

The investigators of this study hypothesize that artificial intelligence (AI) is a useful technology for the screening of diabetic retinopathy (DR) that can detect the absence or the presence of DR with an efficiency and an accuracy similar to that of an ophthalmological evaluation.

The goal of this study is to compare the screening results of DR obtained with NeoRetina pure artificial intelligence algorithm (automated analysis of color photos of the retina) with the results of a routine ophthalmological evaluation done in a clinical context at the Centre hospitalier de l'Université de Montréal (CHUM).

The main objective of this study is to determine if artificial intelligence (AI) could be a useful technology for the early detection and the follow-up of diabetic retinopathy (DR).

The first specific objective is to determine the efficiency and the accuracy of NeoRetina (DIAGNOS Inc.) automated algorithm for the screening and the grading of the severity of diabetic retinopathy (DR) by the analysis of eye fundus images from diabetic patients compared to that of an eye examination done by an ophthalmologist in a clinical context.

The second specific objective is to evaluate if NeoRetina can determine, with efficiency and accuracy, the absence of diabetic retinopathy (DR), the presence of diabetic retinopathy (DR) and the severity of the disease.

Recruited diabetic participants will be screened for DR by AI with NeoRetina. Participants will also have a full eye examination (blind assessment) with an ophthalmologist of the CHUM in order to determine if they suffer from this eye complication of diabetes.

The results of the screening done by AI with NeoRetina will be compared to those of the ocular evaluation done by an ophthalmologist. Ophthalmologists from the CHUM will also revise the retinal images acquired by DIAGNOS (blind assessment) in order to determine if DR is present and will manually grade the severity of the disease.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 630
• Est. completion date: December 2026
• Est. primary completion date: April 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients of 18 years old and older;

2. Ability to provide informed consent;

3. Diagnostic for diabetes : 3a) Type 1 diabetes of a lest 5 years of evolution; or 3b) Type 2 diabetes;

4. Diabetic patient followed and refered by a physician of the Centre hospitalier de l'Université de Montréal (CHUM) : 4a) followed by an endocrinologist of the CHUM; or 4b) hospitalized at the CHUM; or 4c) on the waiting list of the Ophthalmology Clinic of the CHUM for the evaluation of DR.

Exclusion Criteria:

1. Patients less than 18 years old;

2. Inability to provide informed consent;

3. Patient who already had a treatment (surgery, laser, injection, etc.) for any retinal condition : Age-related macular degeneration (AMD), retinal vascular occlusion (RVO); etc.

Related Conditions & MeSH terms

• Diabetic Macular Edema
• Diabetic Maculopathy
• Diabetic Retinopathy
• Macular Degeneration
• Macular Edema
• Retinal Diseases

Intervention

Diagnostic Test:
• Screening of DR and DME with artificial intelligence using NeoRetina
Macula-centered eye color fundus photos will be acquired by DIAGNOS team using a non-mydriatic digital camera (without pupil dilation). After a numerical treatment, retinal images will be analyzed by NeoRetina artificial intelligence (AI) algorithm in order to find eye lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by NeoRetina according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
• Routine ophthalmological evaluation of DR and DME
Standard of care eye examination (blind assessment) will be performed by an ophthalmologist of the CHUM in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by the doctor according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
• Manual grading of DR and DME by CHUM ophthalmologists based on retinal photographies acquired by Diagnos
Ophthalmologists of the CHUM will revise the macula-centered eye color photos acquired by DIAGNOS in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded (blind assessment) according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Centre hospitalier de l'Université de Montréal (CHUM)	DIAGNOS Inc.

References & Publications (2)

Shaban M, Ogur Z, Mahmoud A, Switala A, Shalaby A, Abu Khalifeh H, Ghazal M, Fraiwan L, Giridharan G, Sandhu H, El-Baz AS. A convolutional neural network for the screening and staging of diabetic retinopathy. PLoS One. 2020 Jun 22;15(6):e0233514. doi: 10.1371/journal.pone.0233514. eCollection 2020. — View Citation

Unité d'évaluation des technologies et des modes d'intervention en santé (UETMIS). Centre hospitalier de l'Université de Montréal. Projet pilote : application de l'intelligence artificielle en ophtalmologie. Revue de la littérature et étude de terrain, phase I. Préparée par Imane Hammana et Alfons Pomp. Février 2020.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Artificial Intelligence - Absence or Presence of Diabetic Retinopathy (DR)	Analysis of retinal images by artificial intelligence (NeoRetina) to determine the absence or the presence of diabetic retinopathy (DR); R0 : No DR; R+ : Presence of DR	Baseline
Primary	Eye Examination - Absence or Presence of Diabetic Retinopathy (DR)	Eye examination done by an ophthalmologist to determine the absence or the presence of diabetic retinopathy (DR) (blind assessment); R0 : No DR; R+ : Presence of DR	Baseline
Primary	Manual Analysis of Retinal Images - Absence or Presence of Diabetic Retinopathy (DR)	Manual analysis of retinal images acquired by Diagnos by an ophthalmologist of the CHUM to determine the absence or the presence of diabetic retinopathy (DR) (blind assessment); R0 : No DR; R+ : Presence of DR	Baseline
Primary	Artificial Intelligence - Severity of Diabetic Retinopathy (DR)	Analysis of retinal images by artificial intelligence (NeoRetina) to grade the severity of diabetic retinopathy (DR); R1 - Mild NPDR: Mild Nonproliferative Diabetic Retinopathy; R2 - Moderate NPDR: Moderate Nonproliferative Diabetic Retinopathy; R3 - Severe NPDR : Severe Nonproliferative Diabetic Retinopathy; R4 - PDR : Proliferative Diabetic Retinopathy	Baseline
Primary	Eye Examination - Severity of Diabetic Retinopathy (DR)	Eye examination done by an ophthalmologist to grade the severity of diabetic retinopathy (DR) (blind assessment); R1 - Mild NPDR: Mild Nonproliferative Diabetic Retinopathy; R2 - Moderate NPDR: Moderate Nonproliferative Diabetic Retinopathy; R3 - Severe NPDR : Severe Nonproliferative Diabetic Retinopathy; R4 - PDR : Proliferative Diabetic Retinopathy	Baseline
Primary	Manual Analysis of Retinal Images - Severity of Diabetic Retinopathy (DR)	Manual revision of retinal images acquired by Diagnos by an ophthalmologist of the CHUM to grade the severity of diabetic retinopathy (DR) (blind assessment); R1 - Mild NPDR: Mild Nonproliferative Diabetic Retinopathy; R2 - Moderate NPDR: Moderate Nonproliferative Diabetic Retinopathy; R3 - Severe NPDR : Severe Nonproliferative Diabetic Retinopathy; R4 - PDR : Proliferative Diabetic Retinopathy	Baseline
Primary	Artificial Intelligence - Absence or Presence of Diabetic Macular Edema (DME)	Analysis of retinal images by artificial intelligence (NeoRetina) to determine the absence or the presence of diabetic macular edema (DME); M0 : No DME; M+ : Presence of DME	Baseline
Primary	Eye Examination - Absence or Presence of Diabetic Macular Edema (DME)	Eye examination done by an ophthalmologist to determine the absence or the presence of diabetic macular edema (DME) (blind assessment); M0 : No DME; M+ : Presence of DME	Baseline
Primary	Manual Analysis of Retinal Images - Absence or Presence of Diabetic Macular Edema (DME)	Manual analysis of retinal images acquired by Diagnos by an ophthalmologist of the CHUM to determine the absence or the presence of diabetic macular edema (DME) (blind assessment); M0 : No DME; M+ : Presence of DME	Baseline
Primary	Artificial Intelligence - Severity of Diabetic Macular Edema (DME)	Analysis of retinal images by artificial intelligence (NeoRetina) to grade the severity of diabetic macular edema (DME); M1 : Non Central DME; M2 : Central DME	Baseline
Primary	Eye Examination - Severity of Diabetic Macular Edema (DME)	Eye examination done by an ophthalmologist to grade the severity of diabetic macular edema (DME) (blind assessment); M1 : Non Central DME; M2 : Central DME	Baseline
Primary	Manual Analysis of Retinal Images - Severity of Diabetic Macular Edema (DME)	Manual analysis of retinal images acquired by Diagnos by an ophthalmologist of the CHUM to grade the severity of diabetic macular edema (DME) (blind assessment); M1 : Non Central DME; M2 : Central DME	Baseline
Secondary	Performance of NeoRetina Algorithm - Diabetic Retinopathy (DR)	The performance of NeoRetina algorithm for the detection and the grading of diabetic retinopathy (DR) will be evaluated.; The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) and area under the receiver operating characteristic curve (AUC, 95% CI) will be calculated.; The levels of agreement will be determined by kappa analyses.	3 years
Secondary	Performance of NeoRetina Algorithm - Diabetic Macular Edema (DME)	The performance of NeoRetina algorithm for the detection and the grading of diabetic macular edema (DME) will be evaluated.; The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) and area under the receiver operating characteristic curve (AUC, 95% CI) will be calculated.; The levels of agreement will be determined by kappa analyses.	3 years

External Links

•   Diabetes Quebec - Understanding Diabetes : Myths and Statistics
•   DIAGNOS Inc.